How Should an IBD Prevention Trial Be Designed?
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izaf212 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Rogier L Goetgebuer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Research Design, Clinical Trials as Topic, Secondary Prevention. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Background
Advances in understanding disease pathogenesis have revealed a preclinical phase of inflammatory bowel disease (IBD), offering a potential window for preventive measures. There is growing interest in trials to prevent IBD in at-risk individuals. However, there is limited guidance on how to set up prevention trials in IBD. This review aims to outline key considerations for designing an IBD prevention trial.
Methods
We conducted a review of the literature, gaining insight from prevention trials in other immune-mediated inflammatory diseases (IMIDs). We focused on considerations to set up a secondary prevention trial regarding design, risk stratification and selection strategies, inclusion and exclusion criteria, endpoints, and ethical considerations.
Results
Across IMIDs in which features predictive of future risk have been identified, trials have leveraged well-characterized at-risk cohorts, biomarkers for disease prediction, and feasible interventions. Key elements to consider include (1) identification and longitudinal monitoring of at-risk individuals based on biomarkers, (2) clear definitions of inclusion and exclusion criteria distinguishing a primary prevention trial to prevent disease in at-risk individuals from a secondary prevention trial in individuals with signs of subclinical disease, (3) use of time-to-event endpoints, (4) risk-benefit balancing in intervention choice, and (5) engagement of at-risk individuals. In IBD, analogous strategies are emerging and first-degree relatives stand out as a group for screening. Significant challenges remain in defining risk thresholds, optimizing endpoints, and selected interventions.
Conclusion
Prevention trials in IBD hold promise but require careful design informed by experiences from other IMIDs. Central to this effort are the development of validated predictive tools, ethically appropriate interventions, and international collaboration to assemble well-powered at-risk cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
- Dr. Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
- Division of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.
ORCID-Profile: Rogier L Goetgebuer, Ryan C Ungaro, Vipul Jairath, Jean-Frédéric Colombel
Zitieren
APA
Goetgebuer, R. L., Ungaro, R. C., Feagan, B. G., Jairath, V., Colombel, J. F., & D'Haens, G. R. A. M. (2025). How Should an IBD Prevention Trial Be Designed?. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf212
Vancouver
Goetgebuer RL, Ungaro RC, Feagan BG, Jairath V, Colombel JF, D'Haens GRAM. How Should an IBD Prevention Trial Be Designed?. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf212
BibTeX
@article{Goetgebuer2025,
author = {Goetgebuer, Rogier L and Ungaro, Ryan C and Feagan, Brian G and Jairath, Vipul and Colombel, Jean-Frédéric and D'Haens, Geert R A M},
title = {How Should an IBD Prevention Trial Be Designed?},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izaf212}
}
EUVIMED